Erqi L Pollom1, Dylann Fujimoto1, Jacob Wynne1, Kira Seiger1, Leslie A Modlin1, Lisa R Jacobs1, Melissa Azoulay2, Rie von Eyben1, Laurie Tupper1, Iris C Gibbs1, Steven L Hancock1, Gordon Li3, Steven D Chang3, John R Adler3, Griffith R Harsh3, Ciara Harraher3, Seema Nagpal4, Reena P Thomas4, Lawrence D Recht4, Clara Y H Choi5, Scott G Soltys6. 1. Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California. 2. Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California; Department of Radiation Oncology, McGill University Health Centre, Montreal, Quebec, Canada. 3. Department of Neurosurgery, Stanford University School of Medicine, Stanford, California. 4. Department of Neurosurgery, Stanford University School of Medicine, Stanford, California; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California. 5. Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California; Department of Radiation Oncology, Santa Clara Valley Medical Center, San Jose, California. 6. Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California. Electronic address: sgsoltys@stanford.edu.
Abstract
PURPOSE: We report a longitudinal assessment of health-related quality of life (HRQOL) in patients with glioblastoma (GBM) treated on a prospective dose escalation trial of 5-fraction stereotactic radiosurgery (25-40 Gy in 5 fractions) with concurrent and adjuvant temozolomide. METHODS: HRQOL was assessed using the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire core-30 (QLQ-C30) general, the EORTC quality of life questionnaire-brain cancer specific module (QLQ-BN20), and the M.D. Anderson Symptom Inventory-Brain Tumor (MDASI-BT). Questionnaires were completed at baseline and at every follow-up visit after completion of radiosurgery. Changes from baseline for 9 predefined HRQOL measures (global quality of life, physical functioning, social functioning, emotional functioning, motor dysfunction, communication deficit, fatigue, insomnia, and future uncertainty) were calculated at every time point. RESULTS: With a median follow-up time of 10.4 months (range, 0.4-52 months), 139 total HRQOL questionnaires were completed by the 30 patients on trial. Compliance with HRQOL assessment was 76% at 12 months. Communication deficit significantly worsened over time, with a decline of 1.7 points per month (P=.008). No significant changes over time were detected in the other 8 scales of our primary analysis, including global quality of life. Although 8 patients (27%) experienced adverse radiation effects (ARE) on this dose escalation trial, it was not associated with a statistically significant decline in any of the primary HRQOL scales. Disease progression was associated with communication deficit, with patients experiencing an average worsening of 13.9 points per month after progression compared with 0.7 points per month before progression (P=.01). CONCLUSION: On this 5-fraction dose escalation protocol for newly diagnosed GBM, overall HRQOL remained stable and appears similar to historical controls of 30 fractions of radiation therapy. Tumor recurrence was associated with worsening communication deficit, and ARE did not correlate with a decline in HRQOL.
PURPOSE: We report a longitudinal assessment of health-related quality of life (HRQOL) in patients with glioblastoma (GBM) treated on a prospective dose escalation trial of 5-fraction stereotactic radiosurgery (25-40 Gy in 5 fractions) with concurrent and adjuvant temozolomide. METHODS: HRQOL was assessed using the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire core-30 (QLQ-C30) general, the EORTC quality of life questionnaire-brain cancer specific module (QLQ-BN20), and the M.D. Anderson Symptom Inventory-Brain Tumor (MDASI-BT). Questionnaires were completed at baseline and at every follow-up visit after completion of radiosurgery. Changes from baseline for 9 predefined HRQOL measures (global quality of life, physical functioning, social functioning, emotional functioning, motor dysfunction, communication deficit, fatigue, insomnia, and future uncertainty) were calculated at every time point. RESULTS: With a median follow-up time of 10.4 months (range, 0.4-52 months), 139 total HRQOL questionnaires were completed by the 30 patients on trial. Compliance with HRQOL assessment was 76% at 12 months. Communication deficit significantly worsened over time, with a decline of 1.7 points per month (P=.008). No significant changes over time were detected in the other 8 scales of our primary analysis, including global quality of life. Although 8 patients (27%) experienced adverse radiation effects (ARE) on this dose escalation trial, it was not associated with a statistically significant decline in any of the primary HRQOL scales. Disease progression was associated with communication deficit, with patients experiencing an average worsening of 13.9 points per month after progression compared with 0.7 points per month before progression (P=.01). CONCLUSION: On this 5-fraction dose escalation protocol for newly diagnosed GBM, overall HRQOL remained stable and appears similar to historical controls of 30 fractions of radiation therapy. Tumor recurrence was associated with worsening communication deficit, and ARE did not correlate with a decline in HRQOL.
Authors: T S Armstrong; T Mendoza; I Gning; I Gring; C Coco; M Z Cohen; L Eriksen; Ming-Ann Hsu; M R Gilbert; C Cleeland Journal: J Neurooncol Date: 2006-04-06 Impact factor: 4.130
Authors: Martin J B Taphoorn; Roger Henriksson; Andrew Bottomley; Timothy Cloughesy; Wolfgang Wick; Warren P Mason; Frank Saran; Ryo Nishikawa; Magalie Hilton; Christina Theodore-Oklota; Arliene Ravelo; Olivier L Chinot Journal: J Clin Oncol Date: 2015-05-26 Impact factor: 44.544
Authors: Eric L Chang; Won Yi; Pamela K Allen; Victor A Levin; Raymond E Sawaya; Moshe H Maor Journal: Int J Radiat Oncol Biol Phys Date: 2003-06-01 Impact factor: 7.038
Authors: W Roa; P M A Brasher; G Bauman; M Anthes; E Bruera; A Chan; B Fisher; D Fulton; S Gulavita; C Hao; S Husain; A Murtha; K Petruk; D Stewart; P Tai; R Urtasun; J G Cairncross; P Forsyth Journal: J Clin Oncol Date: 2004-03-29 Impact factor: 44.544
Authors: Terri S Armstrong; Jeffrey S Wefel; Meihua Wang; Mark R Gilbert; Minhee Won; Andrew Bottomley; Tito R Mendoza; Corneel Coens; Maria Werner-Wasik; David G Brachman; Ali K Choucair; Minesh Mehta Journal: J Clin Oncol Date: 2013-10-07 Impact factor: 44.544
Authors: Nathan S Floyd; Shiao Y Woo; Bin S Teh; Charlotte Prado; Wei-Yuan Mai; Todd Trask; Philip L Gildenberg; Paul Holoye; Mark E Augspurger; L Steven Carpenter; Hsin H Lu; J Kam Chiu; Walter H Grant; E Brian Butler Journal: Int J Radiat Oncol Biol Phys Date: 2004-03-01 Impact factor: 7.038
Authors: Melissa Azoulay; Steven D Chang; Iris C Gibbs; Steven L Hancock; Erqi L Pollom; Griffith R Harsh; John R Adler; Ciara Harraher; Gordon Li; Melanie Hayden Gephart; Seema Nagpal; Reena P Thomas; Lawrence D Recht; Lisa R Jacobs; Leslie A Modlin; Jacob Wynne; Kira Seiger; Dylann Fujimoto; Melissa Usoz; Rie von Eyben; Clara Y H Choi; Scott G Soltys Journal: Neuro Oncol Date: 2020-08-17 Impact factor: 12.300
Authors: Robert Kosztyla; Srinivas Raman; Vitali Moiseenko; Stefan A Reinsberg; Brian Toyota; Alan Nichol Journal: Br J Radiol Date: 2019-05-14 Impact factor: 3.039